-
Je něco špatně v tomto záznamu ?
Nitroglycerin to Ameliorate Coronary Artery Spasm During Focal Pulsed-Field Ablation for Atrial Fibrillation
Y. Malyshev, P. Neuzil, J. Petru, M. Funasako, P. Hala, K. Kopriva, C. Schneider, A. Achyutha, A. Vanderper, D. Musikantow, M. Turagam, SR. Dukkipati, VY. Reddy
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- fibrilace síní * chirurgie MeSH
- katetrizační ablace * metody škodlivé účinky MeSH
- koronární angiografie MeSH
- koronární cévy účinky léků chirurgie patofyziologie MeSH
- koronární vazospasmus * prevence a kontrola MeSH
- lidé středního věku MeSH
- lidé MeSH
- nitroglycerin * aplikace a dávkování terapeutické užití MeSH
- senioři MeSH
- vazodilatancia terapeutické užití aplikace a dávkování MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: In treating atrial fibrillation, pulsed-field ablation (PFA) has comparable efficacy to conventional thermal ablation, but with important safety advantages: no esophageal injury or pulmonary vein stenosis, and rare phrenic nerve injury. However, when PFA is delivered in proximity to coronary arteries using a pentaspline catheter, which generates a broad electrical field, severe vasospasm can be provoked. OBJECTIVES: The authors sought to study the vasospastic potential of a focal PFA catheter with a narrower electrical field and develop a preventive strategy with nitroglycerin. METHODS: During atrial fibrillation ablation, a focal PFA catheter was used for cavotricuspid isthmus ablation. Angiography of the right coronary artery (some with fractional flow reserve measurement) was performed before, during, and after PFA. Beyond no nitroglycerin (n = 5), and a few testing strategies (n = 8), 2 primary nitroglycerin administration strategies were studied: 1) multiple boluses (3-2 mg every 2 min) into the right atrium (n = 10), and 2) a bolus (3 mg) into the right atrium with continuous peripheral intravenous infusion (1 mg/min; n = 10). RESULTS: Without nitroglycerin, cavotricuspid isthmus ablation provoked moderate-severe vasospasm in 4 of 5 (80%) patients (fractional flow reserve 0.71 ± 0.08). With repetitive nitroglycerin boluses, severe spasm did not occur, and mild-moderate vasospasm occurred in only 2 of 10 (20%). Using the bolus + infusion strategy, severe and mild-moderate spasm occurred in 1 and 3 of 10 patients (aggregate 40%). No patient had ST-segment changes. CONCLUSIONS: Ablation of the cavotricuspid isthmus using a focal PFA catheter routinely provokes right coronary vasospasm. Pretreatment with high doses of parenteral nitroglycerin prevents severe spasm.
Farapulse Boston Scientific Inc Menlo Park California USA
Homolka Hospital Prague Czech Republic
Icahn School of Medicine at Mount Sinai New York New York USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014163
- 003
- CZ-PrNML
- 005
- 20240905134322.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jacep.2023.12.015 $2 doi
- 035 __
- $a (PubMed)38385916
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Malyshev, Yury $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 245 10
- $a Nitroglycerin to Ameliorate Coronary Artery Spasm During Focal Pulsed-Field Ablation for Atrial Fibrillation / $c Y. Malyshev, P. Neuzil, J. Petru, M. Funasako, P. Hala, K. Kopriva, C. Schneider, A. Achyutha, A. Vanderper, D. Musikantow, M. Turagam, SR. Dukkipati, VY. Reddy
- 520 9_
- $a BACKGROUND: In treating atrial fibrillation, pulsed-field ablation (PFA) has comparable efficacy to conventional thermal ablation, but with important safety advantages: no esophageal injury or pulmonary vein stenosis, and rare phrenic nerve injury. However, when PFA is delivered in proximity to coronary arteries using a pentaspline catheter, which generates a broad electrical field, severe vasospasm can be provoked. OBJECTIVES: The authors sought to study the vasospastic potential of a focal PFA catheter with a narrower electrical field and develop a preventive strategy with nitroglycerin. METHODS: During atrial fibrillation ablation, a focal PFA catheter was used for cavotricuspid isthmus ablation. Angiography of the right coronary artery (some with fractional flow reserve measurement) was performed before, during, and after PFA. Beyond no nitroglycerin (n = 5), and a few testing strategies (n = 8), 2 primary nitroglycerin administration strategies were studied: 1) multiple boluses (3-2 mg every 2 min) into the right atrium (n = 10), and 2) a bolus (3 mg) into the right atrium with continuous peripheral intravenous infusion (1 mg/min; n = 10). RESULTS: Without nitroglycerin, cavotricuspid isthmus ablation provoked moderate-severe vasospasm in 4 of 5 (80%) patients (fractional flow reserve 0.71 ± 0.08). With repetitive nitroglycerin boluses, severe spasm did not occur, and mild-moderate vasospasm occurred in only 2 of 10 (20%). Using the bolus + infusion strategy, severe and mild-moderate spasm occurred in 1 and 3 of 10 patients (aggregate 40%). No patient had ST-segment changes. CONCLUSIONS: Ablation of the cavotricuspid isthmus using a focal PFA catheter routinely provokes right coronary vasospasm. Pretreatment with high doses of parenteral nitroglycerin prevents severe spasm.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fibrilace síní $x chirurgie $7 D001281
- 650 12
- $a nitroglycerin $x aplikace a dávkování $x terapeutické užití $7 D005996
- 650 12
- $a koronární vazospasmus $x prevence a kontrola $7 D003329
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a katetrizační ablace $x metody $x škodlivé účinky $7 D017115
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a vazodilatancia $x terapeutické užití $x aplikace a dávkování $7 D014665
- 650 _2
- $a koronární angiografie $7 D017023
- 650 _2
- $a koronární cévy $x účinky léků $x chirurgie $x patofyziologie $7 D003331
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Petru, Jan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Funasako, Moritoshi $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Hala, Pavel $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Kopriva, Karel $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Schneider, Christopher $u Farapulse-Boston Scientific, Inc, Menlo Park, California, USA
- 700 1_
- $a Achyutha, Anitha $u Farapulse-Boston Scientific, Inc, Menlo Park, California, USA
- 700 1_
- $a Vanderper, Annelies $u Farapulse-Boston Scientific, Inc, Menlo Park, California, USA
- 700 1_
- $a Musikantow, Daniel $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Turagam, Mohit $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Dukkipati, Srinivas R $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 700 1_
- $a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York, USA; Homolka Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org
- 773 0_
- $w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 10, č. 5 (2024), s. 885-896
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38385916 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134316 $b ABA008
- 999 __
- $a ok $b bmc $g 2143759 $s 1226029
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 10 $c 5 $d 885-896 $e 20240221 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
- LZP __
- $a Pubmed-20240725